Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Fenaux, Pierre; Platzbecker, Uwe; J. Mufti, Ghulam; Garcia‐Manero, Guillermo; Buckstein, Rena; Santini, Valeria; Díez‐Campelo, María; Finelli, Carlo; Cazzola, Mario; İlhan, Osman; A. Sekeres, Mikkael; Falantes, José; Arrizabalaga, Beatriz; Salvi, Flavia; Giai, Valentina; Vyas, Paresh; Bowen, David; Selleslag, Dominik; E. DeZern, Amy; G. Jurcic, Joseph; Germing, Ulrich; S. Götze, Katharina; Quesnel, Bruno; Beyne‐Rauzy, Odile; Cluzeau, Thomas; Voso, Maria-Teresa; Mazure, Dominiek; Vellenga, Edo; L. Greenberg, Peter; Hellström-Lindberg, Eva; M. Zeidan, Amer; Adès, Lionel; Verma, Amit; R. Savona, Michael; Laadem, Abderrahmane; Benzohra, Aziz; Zhang, Jennie; Rampersad, Anita; Dunshee, Diana; G. Linde, Peter; L. Sherman, Matthew; S. Komrokji, Rami; F. List, Alan

doi:10.1056/nejmoa1908892

Public

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Published in New England Journal of Medicine • Jan 8, 2020

Authors:

Pierre Fenaux

Uwe Platzbecker

Ghulam J. Mufti

Abstract

BACKGROUND: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to r...

Subject

Medicine

Myelodysplastic syndromes

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!